CN115836069A - 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐、其制备方法及用途 - Google Patents

一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐、其制备方法及用途 Download PDF

Info

Publication number
CN115836069A
CN115836069A CN202180049183.4A CN202180049183A CN115836069A CN 115836069 A CN115836069 A CN 115836069A CN 202180049183 A CN202180049183 A CN 202180049183A CN 115836069 A CN115836069 A CN 115836069A
Authority
CN
China
Prior art keywords
salt
compound
formula
solvent
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180049183.4A
Other languages
English (en)
Other versions
CN115836069B (zh
Inventor
马昌友
田禾
赵建良
陈东晖
吴舰
徐丹
朱春霞
田舟山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Chia Tai Tianqing Pharmaceutical Co Ltd
Original Assignee
Nanjing Chia Tai Tianqing Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Chia Tai Tianqing Pharmaceutical Co Ltd filed Critical Nanjing Chia Tai Tianqing Pharmaceutical Co Ltd
Publication of CN115836069A publication Critical patent/CN115836069A/zh
Application granted granted Critical
Publication of CN115836069B publication Critical patent/CN115836069B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

本申请公开了一种二氢吡啶并[2,3‑d]嘧啶酮衍生物的盐、其制备方法及用途，所述盐选自富马酸盐、甲磺酸盐、羟基乙磺酸盐、α‑萘磺酸盐、对甲苯磺酸盐、1,2‑乙二磺酸盐、草酸盐、马来酸盐、柠檬酸盐、琥珀酸盐、L‑(+)‑酒石酸盐、马尿酸盐、L‑抗坏血酸盐、L‑苹果酸盐、苯甲酸盐、龙胆酸盐、盐酸盐、硫酸盐或磷酸盐。本申请的二氢吡啶并[2,3‑d]嘧啶酮衍生物的盐可用于乳腺癌、前列腺癌或卵巢癌的治疗。
Figure DDA0004045898970000011

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN202180049183.4A 2020-07-22 2021-07-22 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐、其制备方法及用途 Active CN115836069B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020107112605 2020-07-22
CN202010711260 2020-07-22
PCT/CN2021/107815 WO2022017449A1 (zh) 2020-07-22 2021-07-22 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐、其制备方法及用途

Publications (2)

Publication Number Publication Date
CN115836069A true CN115836069A (zh) 2023-03-21
CN115836069B CN115836069B (zh) 2024-02-06

Family

ID=79728514

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180049183.4A Active CN115836069B (zh) 2020-07-22 2021-07-22 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐、其制备方法及用途

Country Status (7)

Country Link
US (1) US20230286979A1 (zh)
EP (1) EP4186902A4 (zh)
JP (1) JP7499942B2 (zh)
CN (1) CN115836069B (zh)
AU (1) AU2021314419B2 (zh)
CA (1) CA3186568A1 (zh)
WO (1) WO2022017449A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3186565A1 (en) * 2020-07-22 2022-01-27 Lei Miao Unit dosage composition of akt inhibitor
WO2024146599A1 (zh) * 2023-01-06 2024-07-11 南京正大天晴制药有限公司 一种二氢吡啶并[2,3-d]嘧啶酮的衍生物、其制备方法以及医药用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051304A2 (en) * 2003-11-21 2005-06-09 Array Biopharma Inc. Akt protein kinase inhibitors
CN102574852A (zh) * 2009-10-23 2012-07-11 伊莱利利公司 Akt抑制剂
CN113272304A (zh) * 2019-01-29 2021-08-17 南京正大天晴制药有限公司 Akt抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA95641C2 (en) 2006-07-06 2011-08-25 Эррей Биофарма Инк. Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
DE602007011628D1 (de) 2006-07-06 2011-02-10 Array Biopharma Inc Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren
RS52210B (en) 2006-07-06 2012-10-31 Array Biopharma, Inc. CYCLOPENT [D] PYRIMIDINS AS PROTEIN KINASE ACTION INHIBITORS
CA2711782C (en) 2008-01-09 2017-01-03 Array Biopharma Inc. 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors
CN115485276B (zh) * 2020-05-15 2024-05-31 南京正大天晴制药有限公司 氘代akt激酶抑制剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051304A2 (en) * 2003-11-21 2005-06-09 Array Biopharma Inc. Akt protein kinase inhibitors
CN102574852A (zh) * 2009-10-23 2012-07-11 伊莱利利公司 Akt抑制剂
CN113272304A (zh) * 2019-01-29 2021-08-17 南京正大天晴制药有限公司 Akt抑制剂

Also Published As

Publication number Publication date
CA3186568A1 (en) 2022-01-27
JP2023535702A (ja) 2023-08-21
EP4186902A4 (en) 2024-06-05
EP4186902A1 (en) 2023-05-31
CN115836069B (zh) 2024-02-06
JP7499942B2 (ja) 2024-06-14
AU2021314419B2 (en) 2023-12-07
WO2022017449A1 (zh) 2022-01-27
US20230286979A1 (en) 2023-09-14
AU2021314419A1 (en) 2023-03-23
AU2021314419A8 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
EP3294742B1 (en) New (5,8-dimethyl-9-phenyl-5,8-dihydro-6h-pyrazolo[3,4-h)quinazolin-2-yl)-(1h-pyrazol-5-yl)-amines and theri derivatives as igf-1r/1r inhibitors.
CN116669734A (zh) 一种嘧啶并五元氮杂环类衍生物的晶型及其制备方法
JP2016526545A (ja) スルホキシイミン置換キナゾリンならびにｍｎｋ１および／またはｍｎｋ２キナーゼ阻害薬としてのその使用
CN112094269B (zh) 一类饱和六元环并杂环类化合物、制备方法和用途
CN115836069B (zh) 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐、其制备方法及用途
AU2020214258A1 (en) AKT inhibitor
CN109721600A (zh) 一类含氮稠环化合物及其制备方法和用途
WO2017071607A1 (zh) 4H-吡唑并[1,5-α]苯并咪唑类化合物晶型及其制备方法和中间体
KR102136958B1 (ko) 7H-피롤로[2,3-d]피리미딘 화합물의 결정형, 염형 및 그 제조방법
BR112020026052A2 (pt) forma de cristal do composto para a inibição da atividade de cdk4/6 e seu uso
CN115843298B (zh) 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐及晶型
WO2021228223A1 (zh) 氘代akt激酶抑制剂
CN115916350B (zh) Akt抑制剂的单位剂量组合物
CN115703760A (zh) 2,4-二取代嘧啶类细胞周期蛋白依赖性激酶酶抑制剂及其制备方法和应用
CN107849051B (zh) 取代的氨基吡喃衍生物的晶型
CN112028885A (zh) 杂环内酰胺类衍生物、其制备方法及其在医药上的用途
CN114075135B (zh) 含邻氨基吡啶炔基的化合物的盐及其制备方法和应用
EP4382528A1 (en) Crystal form of ripk1 inhibitor, acid salt thereof, and crystal form of acid salt thereof
KR20230051207A (ko) Jak 억제제의 염 형태, 결정형, 이의 제조방법 및 이의 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40089395

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant